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The results of the recently published PARAGON-HF trial with
sacubitril/valsartan1 have left the scientific community
with another formally neutral large-scale trial in heart failure
with preserved ejection fraction (HFpEF). The findings of
the complementary trial, PARALLAX,2 as presented in the
late-breaking trial sessions of the virtual ESC Congress 2020,3
have not really changed this perspective on HFpEF trials,
either. Both trials have generated mixed results, at best, with
PARAGON-HF narrowly missing its primary endpoint and PAR-
ALLAX reaching its primary biomarker-based endpoint, change
in N terminal pro brain natriuretic peptide to Week 12, yet be-
ing neutral for the co-primary endpoint of the change in 6min
walk test distance to Week 24, and for both secondary end-
points related to quality of life and symptom burden.
What currently ignites scientific discussion are the observed
significant interactions for both left ventricular ejection frac-
tion and sex.1 The former appears to be embraced, as it ap-
pears to make sense to many, and the latter is largely
ignored as biological plausibility is questioned. Also, there is
no sign for the sex interaction in the PARADIGM-HF trial (inves-
tigating the effect of sacubitril/valsartan vs. placebo in heart
failure with reduced ejection fraction patients).4 Maybe, the
sex interaction in PARAGON-HF (at a P value for interaction
of <0.006 for the primary endpoint) is a chance finding.
But now, there is some surprising news. In the discussion
of PARALLAX after the presentation in the late-breaking trial
session at the virtual ESC Congress 2020, it was mentioned
that the result for the second primary endpoint of this study
(i.e. the change in 6min walk test distance) also showed a sig-
nificant sex interaction in favour of women with HFpEF hav-
ing a benefit from the use of sacubitril/valsartan vs. placebo.3
This comment sets out to explore whether there could be
biological plausibility for a sex interaction in the effects of
sacubitril/valsartan vs. placebo in HFpEF patients. We suggest
two pathways for this. First, effects of endogenous relaxin
may cause this sex difference. Second, it is conceivable that
the actions of B-type natriuretic peptide (BNP) differ between
atria and ventricles, which might explain the striking differ-
ence (in terms of presence and absence of the sex interac-
tion) between the PARAGON-HF and PARADIGM-HF trials.
Endogenous relaxin-2
At first sight, there could be the following link: angiotensin
type-1 receptor (AT1R) blockers (ARBs) have recently
been shown to completely block the anti-fibrotic effects of
therapeutic relaxin, both in rodent models of renal and car-
diac fibrosis and in human cardiac fibroblasts.5,6 This is attrib-
utable to a direct interaction at receptor level—between
RXFP1, the cognate receptor for relaxin-2, the AT1R, and
the AT2R—and it enables antagonists to each receptor
blocking agonist effects at the other receptors.5 In other
words, ARBs have been shown in these models to completely
nullify relaxin’s anti-fibrotic signalling. Until now, it is incon-
clusive if and which other relaxin effects may be affected by
use of ARBs.
This could be relevant for therapeutic relaxin. Heterogene-
ity of the relaxin effects in RELAX-AHF2 and other trials de-
pending on the underlying therapy with ARBs in the
patients included there are not known yet, but such analyses
could easily be performed.
Considering the situation in the clinical studies with
sacubitril/valsartan, one has to take into account endogenous
relaxin-2. Circulating levels in men are ~300-fold to 500-fold
lower than therapeutic levels.7 In women, the ratio depends
on menopausal status: during the menstrual cycle, relaxin
levels may rise to approximately one-tenth of therapeutic
relaxin levels, and this occurs approximately 10 days
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after the plasma surge of the luteinizing hormone.8 In
post-menopausal women, however, levels are similar to
those determined in men.7 As a result, these facts may serve
to construct a sex difference regarding relaxin-2 and a phar-
macological link to the ARB component of the drug under re-
view (i.e. of the valsartan part of sacubitril/valsartan).
At closer look, however, there are data that render this
hypothesis rather unlikely. The mean age of patients in
PARAGON-HF was 73 years. Most if not all women enrolled
should have been post-menopausal, which effectively abol-
ishes the said sex difference in endogenous relaxin levels.
Moreover, the blockade of relaxin effects by valsartan would
have been present in the active control arm as well—then,
the sex interaction favouring women’s outcome would
rather rest in the sacubitril part of the drug to which we
presently do not see any clue. Further, we also have to rec-
ognize the different design of control groups. PARAGON-HF
encompassed one valsartan-treated control group while
PARALLAX had three control strata of which only one was
on ARBs. For angiotensin-converting enzyme inhibitors, the
second PARALLAX stratum, it has been demonstrated that
they do not interfere with relaxin effects.9 Lastly, if there is
no sex difference regarding circulating relaxin levels, could
receptor interaction (RXFP1–AT1R–AT2R) itself be sex-
dependent? At present, we have no data corroborating this
option (TBD, personal communication). Altogether, these
considerations suggest to us that we should dismiss the re-
laxin hypothesis.
Synthetic human relaxin-2, however, is currently being de-
veloped for HFpEF, and in spite of its unique pleiotropic sig-
nalling, it poses a promising candidate for chronic HFpEF
therapy.10 It will therefore be most interesting to explore in
pre-clinical HFpEF models, for example, the ZSF1 rat, if and
to what extent sacubitril/valsartan interferes with therapeu-
tic relaxin effects.
Potential role of BNP in concert with
androgens
A recent paper by Tsai and co-workers11 may give rise to an
alternative explanation. Those researchers focused on atrial
BNP effects and referred to previous work in mice indicat-
ing tumour necrosis factor (TNF) to induce atrial fibrosis.12
In their work, BNP significantly synergized with TNF and
enhanced TNF-induced atrial fibrosis. Furthermore, one
hallmark of fibrosis induction and collagen deposition,
up-regulation of MMP-2, was also observed in primary hu-
man atrial fibroblasts following BNP challenge. Although
these results need to be confirmed by other researchers,
they raise the possibility that ventricular and atrial BNP ef-
fects on extracellular matrix may differ because in ventri-
cles, BNP is well established to counteract fibrosis.13–15
Androgens play a pro-fibrotic role in many circumstances
and seem to act in a dual-hit fashion in various contexts. In
genetically engineered mice lacking the natriuretic
peptide receptor-A (NPR-A aka GC-A), androgens act to pro-
duce sex-dependent cardiac fibrosis and hypertrophy,16
with no such effect in the wild-type animals. Of note,
down-regulation of NPR-A is a common finding in human
heart failure,17 which renders this model even more rele-
vant. In male rats on chronic angiotensin infusion,18 castra-
tion greatly reduces angiotensin-related hypertension,
cardiac hypertrophy, and fibrosis, and this effect is reversed
by testosterone replacement. Furthermore, relaxin-knockout
mice show cardiac and renal fibrosis in males only while
pulmonary fibrosis is markedly accelerated in males.19
Again, there is no sex-dependent difference in organ fibrosis
in the age-matched wild types in this study.
Against this background, we may hypothesize that in male
HFpEF patients treated with sacubitril/valsartan, elevated
BNP acts as second hit in concert with androgens to increase
atrial fibrosis. This would potentially account for the differ-
ence between PARADIGM-HF vs. PARAGON in terms of
the occurrence of a sex interaction. In heart failure with re-
duced ejection fraction, left atrial changes may be a mere
‘bystander’-type of consequence along the course of disease
progression, while in HFpEF, the left atrium takes a more cen-
tral stage in the pathophysiology of disease progression.20
The strong relation between elevated BNP and the incidence
of atrial fibrillation (with atrial fibrosis a major precondition
to it) is well established.21 It is mainly regarded as association
reflecting heart failure severity, but as we have elaborated
here, it may be causal.
Still a chance finding?
It is still a serious possibility for the described sex interaction
of sacubitril/valsartan vs. placebo in HFpEF, seen in one trial
for sure and suggested for a second one, to be a mere chance
finding, especially in view of the negative result of the study,
which should not allow extrapolation of subgroup analyses.
The use of pre-specified subgroups cannot answer all ques-
tions, if there are unknown confounders. Post-hoc subgroup
analyses have questionable statistical value and can be
hypothesis-generating at best. In PARAGON-HF,22 women
had lower estimated glomerular filtration rate and N terminal
pro brain natriuretic peptide levels at baseline, they were
older and more obese, and they had less presence of coro-
nary artery disease. There were differences regarding region
and race regarding women and men in this trial. Also, there
were regional differences in the effectiveness of the trial with
an effect in western Europe similar to that seen in women
and in those patients receiving mineralocorticoid receptor an-
tagonists. Further, in regard of the therapeutic effect, the sex
Editorial 3275
ESC Heart Failure 2020; 7: 3274–3277
DOI: 10.1002/ehf2.13170
difference mainly related to lesser hospitalizations—it did not
translate into more pronounced improvements of functional
class or KCCQ results in women.
Another plausible explanation could be the pharmacody-
namic effect of sacubitril/valsartan as women have a smaller
volume of distribution than men. A fixed dose regimen may
result in higher effective dose in women. This can be relevant
with regard to the blood pressure-lowering effect of the
medicine.
We have not seen the full PARALLAX results yet, to judge in
full the extent of validation of the interaction finding of
PARAGON-HF in PARALLAX. Furthermore, as already men-
tioned, the control group in PARALLAX was different with
only one of three strata on ARBs. Hence, we will not be able
to settle this issue conclusively here.
In summary, we have attempted to explore two hypothe-
ses—an ARB interaction with endogenous relaxin and an
androgen-dependent pro-fibrotic atrial BNP effect—that
could confer biological plausibility to the apparent sex–
treatment interaction with sacubitril/valsartan in the
PARAGON-HF trial. In the public discussion, a lot of weight
is given to the observed ejection fraction-based interaction.
The sex interaction is similarly strong, but it is largely ignored
so far. Sex differences in ejection fraction are partly used to
explain the PARAGON-HF findings. What if we would regard
sacubitril/valsartan as the first successful therapy for female
patients with HFpEF? Would that be bad for women with
HFpEF? There are very many of them, and we think the
answer to the question is ‘no’. We simply feel that this issue
deserves a closer and more scientific look. Whereas we feel
that the relaxin hypothesis is untenable in this context, it
may be worthwhile spending more experimental effort to in-
vestigate in detail the potentially different effects of BNP at
the atrial as opposed to ventricular level.
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